

Scientific Program

SwissRhythm 21 - 22 November 2024, KKL Luzern



situation as of August 14, 2024

Thursday, 21 November 2024

09:00 - 10:40	Main Session	Etienne Delacrétaç, Lausanne Tobias Reichlin, Bern
09:00 - 09:30	New ESC AF guidelines 2024 into practice	Michael Kühne, Basel
09:30 - 10:00	GLP1 and GIP antagonists in patients with AF	Stefan Bilz, St. Gallen
10:00 - 10:40	PVI: bias in patient selection	John Mandrola, Louisville, USA
10:40 - 11:10 Coffee Break		
11:10 - 12:50	New and Evolving Technologies	Laurent Haegeli, Aarau Andreas Müller, Zürich
11:10 - 11:35	First Experience with the new FARAVIEW mapping integration for Pulsed Field Ablation	Petr Neuzil, Prague, CZ
11:35 - 12:00	The extravascular system with transvenous ICD features: who, why & how	Alexander Breitenstein, Zürich
12:00 - 12:25	Artificial intelligence in rhythm monitoring - present and future	Patrick Badertscher, Basel
12:25 - 12:50	PVI ablation with dual-energy and 3D mapping	Tom De Potter, Aalst, BE
12:50 - 14:00 Lunch		
14:00 - 14:45	Pro / Con Session: Management of asymptomatic AF	Marianne Zimmerli Voegtli, Thun Claudia Herrera Siklódy, Bern
	Ablate	Benjamin Berte, Luzern
	Wait and see	Andreas Flammer, Zürich
14:50 - 16:10	Interactive Case based Workshops	Andrea Menafoglio, Bellinzona Haran Burri, Genève
14:50 - 15:10	How to optimize/troubleshoot PM (DDD/CRT) programming in the modern era	Fabian Noti, Bern
15:10 - 15:30	Management of arrhythmias in an elderly population	Philipp Krisai, Basel
15:30 - 15:50	Diagnosis and management of drug-induced QT prolongation in practice	Giulio Conte, Lugano
15:50 - 16:10	LAA occlusion versus OAC vs. both	Laurent Roten, Bern
16:10 - 16:40 Coffee Break		
16:40 - 17:30	ECG Workshop	Gonca Suna, Zürich Valon Spahiu, Bern

Friday, 22 November 2024

08:30 - 10:30	Main Session	Sven Reek, Aarau Richard Kobza, Luzern
08:30 - 09:00	The future of primary prevention ICDs	Valérian Vallton, Genève
09:00 - 09:30	Pacing: which device for which patient	Peter Ammann, St. Gallen
09:30 - 10:00	Using pulsed Field Ablation for AF ablation	Tobias Reichlin, Bern
10:00 - 10:30	VT in structural heart disease: drugs, ablation, ICD	Ardan Saguner, Zürich
10:30 - 11:00 Coffee Break		
11:00 - 13:05	New and Evolving Technologies	Hildegard Tanner, Bern Michael Kühne, Basel
11:00 - 11:25	Leveraging AI and Digital Twins for the definition of novel, personalized therapies	Alfredo Hernandez, Clamart, FR
11:25 - 11:50	To extract or not to extract – borderline indications in transvenous lead management	Andreas Häberlin, Bern
11:50 - 12:15	Real-World Clinical Case Discussions	Nadine Molitor, Zürich
12:15 - 12:40	First Swiss experience with the AVEIR AR/DR Leadless pacemaker	Daniel Hofer, Zürich
12:40 - 13:05	An immersive catheter ablation platform based on patients' 3D heart model for the simulation and training of future electrophysiologists	Etienne Pruvot, Lausanne
13:05 - 13:35	Hot topics in 2024	Etienne Delacrétaç, Lausanne
13:05 - 13:20	Resynchronization therapy BiVP or CSP	Giulia Domenichini, Lausanne
13:20 - 13:35	Anticoagulation for device-detected AF: My practice after the NOAH and ARTESIA trials	Christian Sticherling, Basel
13:35 - 14:30 Farewell and Lunch		